Company Description
Sonoma Pharmaceuticals, Inc. develops and produces stabilized hypochlorous acid (HOCl) products for wound and eye care, oral and nasal care, podiatry, animal health care, and dermatological conditions in the United States, Europe, Asia, Latin America, and internationally.
It offers Lumacyn, a skin toner; Regenacyn, a prescription scar gel; Reliefacyn to alleviate red bumps, rashes, shallow skin fisures, sunburn, peeling, and eczema/atopic dermatitis; Gramaderm for the treatment of topical mild to moderate acne; Epicyn, an antimicrobial facial cleanser; Levicyn, an HOCl based prescription and over-the-counter product used to relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and Pediacyn, an atopic dermatitis hydrogel.
The company also provides Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a range of pathogens; Ocucyn eyelid and eyelash cleanser; Ocudox for eye care; Sinudox for nasal irrigation; Microdacyn60 oral care solution to treat mouth and throat infections; and Podiacyn, a foot care product.
In addition, it offers MicrocynAH, an HOCl-based solution used to relieve common symptoms of hot spots, scratches, skin rashes, post-surgical sites, and irritated animal skin; MicrocynVS, an animal care product; Nanocyn, a hospital-grade disinfectant; Acuicyn, a solution for the treatment of blepharitis and the daily hygiene of eyelids and lashes; MucoClyns, a disinfectant; and Endocyn, a root canal irrigation solution.
The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016.
Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Boulder, Colorado.
| Country | United States |
| Founded | 1999 |
| IPO Date | Jan 25, 2007 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 8 |
| CEO | Amy Trombly |
Contact Details
Address: 5445 Conestoga Court, Suite 150 Boulder, Colorado 80301 United States | |
| Phone | 800 759 9305 |
| Website | sonomapharma.com |
Stock Details
| Ticker Symbol | SNOA |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | April - March |
| Reporting Currency | USD |
| CIK Code | 0001367083 |
| CUSIP Number | 83558L303 |
| ISIN Number | US83558L3033 |
| Employer ID | 68-0423298 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Amy M. Trombly Esq., J.D. | Chief Executive Officer, President and Director |
| Jerome J. Dvonch C.P.A. | Chief Financial Officer |
| Bruce Thornton | Executive Vice President, Chief Operating Officer and Corporate Secretary |
| John Dal Poggetto | Controller |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 7, 2025 | 10-Q | Quarterly Report |
| Jul 11, 2025 | DEF 14A | Other definitive proxy statements |
| Jun 17, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Jun 17, 2025 | 10-K | Annual Report |
| Apr 28, 2025 | 8-K | Current Report |
| Apr 7, 2025 | 8-K | Current Report |
| Mar 25, 2025 | 8-K | Current Report |
| Feb 5, 2025 | 10-Q | Quarterly Report |
| Jan 30, 2025 | 8-K | Current Report |
| Jan 3, 2025 | 8-K | Current Report |